Bladder Urothelial Carcinoma In Situ — Trials

Bladder Urothelial Carcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 33%
Top sponsor: AC.TA. S.r.l.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–10 of 10 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07189793	Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study(OHAI-NMIBC-01)	not yet recruiting	Phase 2	106	First Affiliated Hospital of Wenzhou Medical UniversityOTHER	1	Sep 8, 2026	clinicaltrials
NCT04164082	Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer	active not recruiting	Phase 2	161	National Cancer Institute (NCI)